Navigation Links
Cardium and Tissue Repair Company's Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
Date:3/17/2008

had limited success, including treatment of dermal wounds (such as diabetic foot ulcers), therapeutic angiogenesis (pharmacologically inducing new blood vessel growth), and orthopedic products for repair of various tissues, including hard tissue (bone) and soft tissue (ligament, tendon, cartilage).

About Cardium

Cardium Therapeutics, Inc. and its subsidiaries, InnerCool Therapies, Inc. and the Tissue Repair Company, are medical technology companies primarily focused on the development, manufacture and sale of innovative therapeutic products and devices for cardiovascular, ischemic and related indications. Cardium's lead product candidate, Generx (alferminogene tadenovec, Ad5FGF-4), is a DNA-based growth factor therapeutic being developed for potential use by interventional cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina. For more information about Cardium Therapeutics and its businesses, products and therapeutic candidates, please visit http://www.cardiumthx.com.

Cardium's InnerCool Therapies subsidiary is a San Diego-based medical technology company in the emerging field of temperature modulation therapy to rapidly and controllably cool the body in order to reduce cell death and damage following acute ischemic events such as cardiac arrest or stroke, and to potentially lessen or prevent associated injuries such as adverse neurological outcomes. For more information about Cardium's InnerCool subsidiary and therapeutic hypothermia, including InnerCool's Celsius Control System(TM), which has received regulatory clearance in the U.S., Europe and Australia, please visit http://www.innercool.com.

Cardium's Tissue Repair Company subsidiary (TRC) is a San Diego-based biopharmaceutical company focused on the develop
'/>"/>

SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Study Finds Starion Instruments Tissue Welding Technology Safe and Effective in Parotidectomy Procedures
2. Knee Pain? An Exclusive Study Engineers Cartilage to Match Patients Own Tissue
3. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
4. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
5. Study Finds Starion Instruments Tissue Welding Technology Reduces Pain and Bleeding in Tonsillectomy Patients
6. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
7. BioMosaics Glypican-3 Blood & Tissue Tests Receive CE Marking in Europe
8. National Stem Cell Holding, Inc. Discovers Non-Embryonic Biomaterials that Promote Tissue Repair
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.
11. GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)...  The Healthcare Analytics Summit 2014 (HAS ... Salt Lake City , Sept. 24-25 has added ... organizations in the U.S. and beyond.  HAS ,14, powered ... devoted to providing immersive learning experiences on the ... accountable care initiatives and population health managemen t ...
(Date:7/29/2014)... MOUNTAIN VIEW, Calif. , July 29, 2014 ... antivirals has amplified with rising incidence rates and ... absence of a preventative vaccine. Change is underway ... and interferon regimens towards highly effective, easily-tolerated, interferon-free ... http://photos.prnewswire.com/prnh/20140728/130662 Gilead,s mega blockbuster ...
(Date:7/29/2014)... LONDON , July 29, 2014 ... 2014 Global Frost & Sullivan Best Practices Award ... solution is a cloud-based platform that connects digital ... - such as providers, pharmaceutical companies, prevention and ... electronics. Each year, Frost & ...
Breaking Medicine Technology:Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 2Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 3Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 4Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 5A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 3A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 4Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 2Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 3Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 4
... ZURICH , July 19, 2010 Today, Novo Nordisk ... designed to investigate the effects of modern insulins in,the management of type 2 diabetes.[1] ... Spanning 28 countries across ... largest observational study,in insulin therapy. , , ...
... July 16 Human erythropoietin (EPO) is a ... and spinal cord injury, and Parkinson,s disease. However, EPO drug ... cross the blood-brain barrier (BBB). In acute stroke or brain ... the insult when neuroprotection is still possible. Therefore, large molecule ...
Cached Medicine Technology:World's Largest Study on Insulin Therapy Completes Recruitment With 60,000 Patients 2World's Largest Study on Insulin Therapy Completes Recruitment With 60,000 Patients 3ArmaGen® Re-engineers Erythropoietin for Brain Penetration 2
(Date:7/29/2014)... rates rise in association with extremely hot weather. The ... 2003, for example, resulted in about 22,000 extra deaths. ... at the Institute of Epidemiology II at the Helmholtz ... the number of deaths caused by cardiovascular disease in ... temperatures in the study. , "Our findings confirm the ...
(Date:7/29/2014)... handle stressful situations better than others, and it,s ... show differences in how they respond. , Researchers ... brains of genetically identical mice that predicts how ... , The findings, published July 29 in ... prevent potential consequences of chronic stress -- such ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Foot Levelers ... lecturer at the Florida Chiropractic Association (FCA) National Convention ... Effects on the Kinetic Chain Changes on Thursday, August ... talk is focusing on the positive impact functional foot ... such as low back pain, plantar fasciitis, and hammertoes. ...
(Date:7/29/2014)... Dallas, Texas (PRWEB) July 29, 2014 ... the Global Biosimilars Market report is an essential ... biosimilars industry. Using detailed company data, financial analysis, ... in-depth analysis of the current and future growth ... the various regulatory frameworks under which biosimilars are ...
(Date:7/29/2014)... Catalent Pharma Solutions, the global leader ... for pharmaceutical, biologic, and consumer health products, today ... US Platform Leader of Pharmaceutical Softgels, will present ... Formulations using Soft Capsule Delivery Systems” at the ... of Drug Delivery Systems (30-31 July 2014, Tokyo, ...
Breaking Medicine News(10 mins):Health News:Mortality rates increase due to extreme heat and cold 2Health News:A new brain-based marker of stress susceptibility 2Health News:Foot Levelers CEO Kent Greenawalt Speaking at FCA Convention 2Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 2Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 3Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 4Health News:Catalent Expert to Present on Enhancing Bioavailability of Poorly Absorbed Drugs at Japan Society of Drug Delivery Systems 2
... say the drug clodronate is an effective treatment for patients ... studied more than 1,000 patients // with breast cancer. Patients ... day or a placebo for five years. ,Results showed ... to their bones. Fifty-one of these patients were treated with ...
... identified a protein that essentially blocks HIV replication, in ... is not as effective at stopping HIV, say the ... of Nature. The team, headed by Joseph Sodroski, is ... Infectious Diseases (NIAID). ,"Identification of this HIV-blocking ...
... According to recent findings researchers say the risks and ... to be re-evaluated.// Researchers from Sweden studied more than ... of age. Participants had their intellectual capacity tested at ... school attendance records for the young men. ,Results ...
... pressure at home may lead to fewer blood pressure ... at patients’ homes to conventional doctors’ office measurements of ... patients with a diastolic blood pressure reading of 95 ... offices were included for the study. All of the ...
... a new treatment can now help chronic chest pain sufferers ... other antianginal medications it was found to improve the total ... ,Ranolazine is currently under review by the FDA. ... angina were randomly assigned to receive a placebo or one ...
... a non-surgical technique used to eliminate alternate pathways ... // Researchers now say that congestive heart failure ... of irregular heart rhythm experience significant improvement ... catheter ablation. ,58 patients with congestive heart ...
Cached Medicine News:
... The new Guidant VASOVIEW® ... to deliver a new level ... harvesting for both the saphenous ... simultaneous cut-and-seal capability, it lets ...
...
... Now rapid intrapartum or antepartum GBS results ... versus 2 days. This revolutionary in vitro diagnostic ... designed to be run in the clinical lab ... and delivery nurses 24 hours a day, ...
... contains primers and a FAM-labeled probe that is ... the mecA gene. In addition, this ASR contains ... an internal control sequence. This ASR requires an ... reporter dyes such as the Cepheid SmartCycler System. ...
Medicine Products: